WIN 70197

Drug Profile

WIN 70197

Alternative Names: WIN-70197

Latest Information Update: 08 Sep 2006

Price : $50

At a glance

  • Originator Amersham Health; Sanofi Winthrop
  • Class Gadolinium-containing contrast agents; Radiopharmaceuticals
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Liver disorders

Most Recent Events

  • 08 Sep 2006 Discontinued - Preclinical for Liver disorders diagnosis in USA (unspecified route)
  • 16 Nov 1998 No development reported - Preclinical for Liver disorders diagnosis in USA (unspecified route)
  • 24 Jan 1997 Preclinical development for Liver disorders diagnosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top